The purpose of the study is to learn about a possible new medicine, apremilast, for treating
acute gout and compare how it works to indomethacin, a medication that has been used to treat
gout for over 50 years.
In order to learn about apremilast, half the participants in this study will receive
apremilast and half the participants in this study will receive indomethacin.
This study will measure the severity and duration of acute gout attacks in research
participants, as well as measures of quality of life and any side effects or adverse
reactions to the medication.
There will be three study visits: a screening/baseline visit on Day 1, a visit to evaluate
response to treatment with study medication at Day 7, and a follow-up visit at Day 21.